Berenson JR - Search Results

1

Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.

Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Coleman RE, et al. Among authors: berenson jr. Clin Cancer Res. 2008 Oct 15;14(20):6387-95. doi: 10.1158/1078-0432.CCR-08-1572. Clin Cancer Res. 2008. PMID: 18927277 Free PMC article. Review.

2

Pharmacology and clinical efficacy of bisphosphonates.

Berenson JR, Lipton A. Berenson JR, et al. Curr Opin Oncol. 1998 Nov;10(6):566-71. doi: 10.1097/00001622-199811000-00015. Curr Opin Oncol. 1998. PMID: 9818237 Review.

3

Use of bisphosphonates in patients with metastatic bone disease.

Berenson JR, Lipton A. Berenson JR, et al. Oncology (Williston Park). 1998 Nov;12(11):1573-9; discussion 1579-81. Oncology (Williston Park). 1998. PMID: 9834935 Free article. Review.

4

Bisphosphonates in the treatment of malignant bone disease.

Berenson JR, Lipton A. Berenson JR, et al. Annu Rev Med. 1999;50:237-48. doi: 10.1146/annurev.med.50.1.237. Annu Rev Med. 1999. PMID: 10073275 Review.

5

Bisphosphonate treatment of lytic bone metastases.

Lipton A, Berenson JR. Lipton A, et al. Among authors: berenson jr. Drugs Aging. 1999 Apr;14(4):241-6. doi: 10.2165/00002512-199914040-00001. Drugs Aging. 1999. PMID: 10319239 Review.

6

Oral bisphosphonates: A review of clinical use in patients with bone metastases.

Major PP, Lipton A, Berenson J, Hortobagyi G. Major PP, et al. Cancer. 2000 Jan 1;88(1):6-14. Cancer. 2000. PMID: 10618600 Review.

7

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG. Hillner BE, et al. Among authors: berenson jr. J Clin Oncol. 2000 Mar;18(6):1378-91. doi: 10.1200/JCO.2000.18.6.1378. J Clin Oncol. 2000. PMID: 10715310

8

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ. Berenson JR, et al. Cancer. 2001 Apr 1;91(7):1191-200. doi: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0. Cancer. 2001. PMID: 11283917 Clinical Trial.

9

A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.

Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A. Berenson JR, et al. Clin Cancer Res. 2001 Mar;7(3):478-85. Clin Cancer Res. 2001. PMID: 11297237 Clinical Trial.

10

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS; American Society of Clinical Oncology Bisphosphonates Expert Panel. Berenson JR, et al. J Clin Oncol. 2002 Sep 1;20(17):3719-36. doi: 10.1200/JCO.2002.06.037. J Clin Oncol. 2002. PMID: 12202673

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters